NCT06498063 The Underlying Mechanisms Regarding the Effect of Glucagon on the Kidneys Will be Investigated in Healthy Males.
| NCT ID | NCT06498063 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ali Asmar |
| Condition | Kidney Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2024-02-20 |
| Primary Completion | 2025-03-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2024-02-20 with a primary completion date of 2025-03-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this crossover study is to investigate to what extend glucagon affects the kidneys. The main questions it aims to answer are: Does glucagon regulate kidney function through extraction in the kidney in addition to glomerular filtration? Does glucagon regulate kidney function by increasing renal plasma flow and glomerular filtration rate? Does glucagon regulate kidney function by increasing renal salt excretion?
Eligibility Criteria
Inclusion Criteria: * Age: 20-60 years * Normal health ascertained through questioning and medical examination * Normal values for blood concentrations of fasting plasma glucose, fasting plasma total cholesterol, fasting triglycerides, HDL, LDL, creatinine, liver function, and electrolytes * Informed consent Exclusion Criteria: * Immunosuppressive treatment in the preceding 12 months * Alcohol abuse * Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists, which, in the opinion of the investigator, may interfere with glucose metabolism * Use of lithium * Medical treatment that affects insulin secretion or cardiovascular performance measures * Liver disease (ALT \> 2x normal value) * Renal impairment (se-creatinine \> 130 μM and/or albuminuria)
Contact & Investigator
Ali Asmar, MD
PRINCIPAL INVESTIGATOR
Bispebjerg Hospital
Frequently Asked Questions
Who can join the NCT06498063 clinical trial?
This trial is open to male participants only, aged 20 Years or older, up to 60 Years, studying Kidney Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06498063 currently recruiting?
Yes, NCT06498063 is actively recruiting participants. Contact the research team at ali.asmar.02@regionh.dk for enrollment information.
Where is the NCT06498063 trial being conducted?
This trial is being conducted at Copenhagen, Denmark.
Who is sponsoring the NCT06498063 clinical trial?
NCT06498063 is sponsored by Ali Asmar. The principal investigator is Ali Asmar, MD at Bispebjerg Hospital. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.